Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$3.12 ▲ +0.02
(+0.65%)
MKT CAP: $542.6M • VOL: 141.0K
52W L $1 52W H $4
ROARABLE / RQD
D- • 40/100
PIOTROSKI
2 / 9
ENTX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $42.0K | $181.0K | $0 |
| YoY Revenue Growth % | -76.8% | — | — |
| Gross Profit | $0 | $9.0K | — |
| Gross Margin % | 0.0% | 5.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$11.5M | -$9.6M | -$8.9M |
| Operating Margin % | -80.0% | -80.0% | — |
| Net Income (GAAP) | -$11.4M | -$9.5M | -$8.9M |
| EBITDA (Normalized) | -$11.4M | -$9.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$7.4M | -$6.8M | -$7.3M |
| Capital Expenditures (CapEx) | $107.0K | $3.0K | — |
| Free Cash Flow (FCF) | -$7.5M | -$6.8M | -$7.3M |
| FCF Margin % | -80.0% | -80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $7.1M | $8.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $13.1M | $8.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ENTX.